Search Results 1501-1510 of 38834 for Two-phase

1. Migraine with aura - Symptoms & causes - Mayo Clinic

   You can try to prevent migraine with aura using self-care steps such as following a regular sleep and meal schedule and avoiding things that may trigger ...

2. Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis - Mayo Clinic

   Study phase. 1/2. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase ( ...

3. Labor induction - Mayo Clinic

   An infection in the uterus. Other reasons for labor induction include: Labor that hasn't started on its own one or two weeks after the due date. At ...

4. A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 Positive, Metastatic Pancreatic Adenocarcinoma - Mayo Clinic

   The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and ...

5. Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Study phase. 1/2. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase ( ...

6. A Study to Evaluate the Safety and Effectiveness of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease - Mayo Clinic

   Phase 2 - The purpose is to evaluate the effectiveness of AMG 592 in subjects with steroid refractory cGVHD as measured by ORR at 16 weeks according to the ...

7. Chronic Myelomonocytic Leukemia Clinical Trials - Mayo Clinic Research

   A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR) of tipifarnib in approximately 20 eligible subjects with CMML.

8. Atezolizumab (intravenous route) - Side effects & uses - Mayo Clinic

   It is given to patients who have stage 2 to stage 3A NSCLC and whose tumors express PD-L1. Your doctor will perform a test to check for the PD-L1 tumor ...

9. A Study to Evaluate KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis - Mayo Clinic

   Overview. Tab Title Description. Study typeInterventional Study phase2. Study ... (two doses) or matched placebo for 28 weeks. The study will be double ...

10. A Study to Evaluate the Safety and Tolerability of KTE-X19 in Adults with Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma - Mayo Clinic

    Study phase. 1. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase ...